Advanced Brain Monitoring Inc was named the “Most Innovative Medical Device Company” by Global Health and Pharma at its 2016 Healthcare and Pharmaceutical awards. “This award recognizes our company’s successes in developing technologies which enable clinicians and clinical trial sponsors to profile brain health through the analysis of the brain’s electrical activity (EEG) during sleep and wake,” says Chris Berka, Advanced Brain Monitoring CEO, in a release.
The company’s platform includes streamlined EEG acquisition, secure transmission over a cloud portal, and rapid analyses and reporting. The functional Neuro-Electrophysiological Imaging (fNEI) simultaneously measures EEG during resting state or with concurrent neurocognitive tests to activate the neural circuits involved in attention, memory, and emotion. Quantified data can be compared to a database of more than 10,000 sessions from healthy and impaired populations. “Preliminary results reveal potential for estimating the severity of brain impairment for Alzheimer’s and Parkinson’s disease, mild cognitive impairment, and Frontotemporal dementia,” says Philip Westbrook, chief medical officer.
Sleep Profiler explores the functioning of the brain during sleep and detects biomarkers associated with neurodegeneration and chronic diseases. Clinical applications include objectively assessing efficacy of prescription sleeping aids for patients with insomnia or the impact of anti-depressants and antihypertensive medications on sleep quality. “Sleep Profiler biomarkers have also been associated with the brain patterns of intensive care unit (ICU) patients who had sepsis or died,” says Daniel J. Levendowski, president. “Sleep Profiler will soon enable the real-time monitoring of abnormal sleep patterns in ICU patients.”
The company was recently awarded a $1.5 mm grant from National Institute of Health to expand its database of awake and sleep EEG in patients with neurodegenerative diseases. “The envisioned future is for routine brain health assessments during sleep and waking to be conducted in a manner similar to a mammogram or colonoscopy,” says Berka. “Ultimately, early detection will increase the likelihood that an intervention can be matched to the patient based on the presence of brain biomarkers and administered prior to the onset of cognitive decline.”